Eletriptan vs Rizatriptan: Which Migraine Drug Works Better?

Eletriptan and rizatriptan are two of the most effective oral triptans for acute migraine, and head-to-head data suggest they perform almost identically at the two-hour mark. Where they start to diverge is over the following 24 hours and in which other medications you take alongside them. Those differences, rather than raw pain-relief speed, tend to be what actually tips the choice for a given person.

How They Stack Up at Two Hours

The standard yardstick for any migraine drug is whether it relieves pain within two hours. A large comparative review of triptan trials found that oral eletriptan 40 mg and oral rizatriptan 10 mg each produced a therapeutic gain of about 37 percentage points over placebo for two-hour headache response, making them statistically indistinguishable on this measure.¹ A separate review of eletriptan’s clinical profile reached the same conclusion, describing eletriptan 40 mg as equivalent to rizatriptan 10 mg across most efficacy endpoints.² If your only concern is knocking out a migraine within the first couple of hours, neither drug has a clear advantage over the other at their standard doses.

That parity changes when the dose of eletriptan goes up. The 80 mg dose of eletriptan was found to be superior to zolmitriptan 2.5 mg on most efficacy measures, suggesting there is headroom in eletriptan’s dosing that rizatriptan, typically capped at 10 mg per dose, does not offer in the same way.³ This matters mostly for people who find that a standard dose takes the edge off but does not fully resolve the attack.

The 24-Hour Picture

Two-hour relief does not always mean the migraine stays gone. Recurrence, where pain creeps back within 24 hours of initial relief, is one of the most frustrating aspects of triptan therapy. This is where eletriptan starts to separate itself from the pack. A network meta-analysis comparing all oral triptans found that eletriptan consistently yielded the highest treatment-effect estimates. For 24-hour endpoints, eletriptan was statistically superior to rizatriptan for at least one sustained outcome.⁴

Why does eletriptan hold up better over a full day? Part of the explanation is pharmacokinetic: eletriptan has a longer half-life than rizatriptan. Rizatriptan is cleared from the body relatively quickly, which can leave a window for the migraine to reassert itself. Eletriptan hangs around longer, maintaining receptor activity through the period when recurrence is most likely. If your migraines tend to come roaring back a few hours after the initial dose wears off, eletriptan’s sustained profile is a meaningful advantage.

When One Fails, Can You Switch to the Other?

A common situation in migraine care is that a patient responds well to a triptan for a while and then finds it less effective, or never gets a great response from the first one tried. A study specifically recruiting patients who reported an unsatisfactory response to rizatriptan found that eletriptan still provided meaningful relief for many of them, with a recurrence rate of roughly 37%.⁵ That recurrence figure is not spectacular in isolation, but the fact that a different triptan worked at all for people who had given up on rizatriptan is the clinically useful takeaway. The two drugs bind to the same family of serotonin receptors but have different enough pharmacological profiles that switching from one to the other is not like trying the same thing twice.

This switching logic goes both directions. If eletriptan does not work for you, rizatriptan is a reasonable next trial. Doctors generally recommend trying at least two or three different triptans before concluding that the entire drug class is ineffective for a given patient. Because eletriptan and rizatriptan are processed through different metabolic pathways in the liver, the reasons one fails may not apply to the other at all.

Drug Interactions Are Where They Really Differ

The most practically important distinction between these two drugs is not how well they relieve pain but which other medications they clash with. Eletriptan is broken down primarily by the liver enzyme CYP3A4.⁶ That means anything that strongly inhibits CYP3A4 can cause eletriptan levels in your blood to spike. The classic offenders include certain antifungal medications (ketoconazole, itraconazole), some HIV protease inhibitors, and the antibiotic clarithromycin. If you take any of these regularly, eletriptan is typically off the table, and rizatriptan becomes the better choice by default.

Rizatriptan, by contrast, is partly broken down by monoamine oxidase (MAO). That makes it the one to avoid if you take an MAO inhibitor, a class of drugs still used for depression and sometimes Parkinson’s disease. MAO inhibitors slow rizatriptan’s clearance enough to cause dangerously elevated levels.⁷ In that scenario, eletriptan is the safer pick. There is also a well-known interaction between rizatriptan and propranolol, a beta-blocker often prescribed as a migraine preventive. Propranolol raises rizatriptan blood levels, so the typical recommendation is to reduce the rizatriptan dose to 5 mg when both are used together. Eletriptan does not share that interaction.

The bottom line on interactions: your medication list can make the decision for you, regardless of which drug is theoretically “better.” This is one reason headache specialists ask about every pill and supplement you take before writing a triptan prescription.

Side Effects and Central Nervous System Symptoms

Both eletriptan and rizatriptan are generally well tolerated, and a head-to-head preference trial found no meaningful difference in overall tolerability between the two.⁸ Where they do stand out, and not in a flattering way, is in central nervous system side effects relative to other triptans. A review of CNS-related adverse effects across the triptan class found that eletriptan (both 40 and 80 mg), rizatriptan 10 mg, and zolmitriptan had the highest rates of symptoms like dizziness, drowsiness, and a foggy or “spacey” feeling. In contrast, almotriptan and sumatriptan at lower doses had the lowest CNS side-effect rates.⁹

The likely explanation involves two things: lipophilicity and active metabolites. Both eletriptan and rizatriptan produce active metabolites when the body processes them, and both parent compounds cross into the brain relatively easily. That is probably part of why they work so well against migraine, but it also means they are more likely to produce noticeable neurological side effects.¹⁰ For most people these effects are mild and short-lived, but if you find that one of them makes you unacceptably drowsy or foggy, switching to the other is unlikely to solve that specific problem since the mechanism is shared. You would need to try a triptan from a different pharmacological corner, like almotriptan or naratriptan.

Beyond CNS effects, the common triptan side-effect profile applies to both: a feeling of chest tightness or pressure, tingling in the extremities, flushing, and sometimes mild nausea. These are class effects related to serotonin receptor activation and tend to occur at similar rates with both drugs.

Consistency Across Multiple Attacks

One underappreciated dimension of triptan performance is whether it works reliably attack after attack, not just on average across a clinical trial. A migraine that responds beautifully to a drug one month but not the next is almost as frustrating as having no treatment at all. Eletriptan has been studied specifically for this within-patient consistency. In a randomized multi-attack trial, about 77% of patients on eletriptan 40 mg achieved a headache response in at least two out of three treated attacks, and roughly 46% responded in all three.¹¹ The probability of achieving a headache response at two hours on any given attack ranged from about 71% to 74% with eletriptan 40 mg, compared with 17% to 28% on placebo.¹²

Rizatriptan has not been as extensively studied with this particular within-patient consistency design, so a direct comparison on this metric is hard to make. That said, rizatriptan’s overall efficacy in large trials is similar enough that there is no strong reason to assume it would score dramatically differently. The eletriptan data is reassuring for anyone worried about reliability, but absence of parallel rizatriptan data should not be read as evidence of inferiority.

Cost-Effectiveness

Both drugs now exist as generics, which has dramatically leveled the playing field on price. Pharmacoeconomic analyses conducted when branded versions still dominated the market consistently found eletriptan 40 mg and rizatriptan 10 mg among the most cost-effective oral triptans available. One review concluded that eletriptan 40 mg sat in a cluster with rizatriptan 10 mg and almotriptan 12.5 mg as the best value, a finding that held whether “efficacy” was defined as two-hour pain-free, sustained pain-free, or sustained pain-free without adverse events.¹³

A Swedish cost-effectiveness model reached a similar conclusion: all other oral triptans were dominated (meaning they cost more and worked worse) when compared to rizatriptan 10 mg and eletriptan 40 mg. The incremental cost of choosing rizatriptan over eletriptan for one additional sustained pain-free episode without adverse events was about 100 euros, a small margin that did not clearly favor one over the other.¹⁴ A broader six-country analysis also found sumatriptan 100 mg, rizatriptan 10 mg, and eletriptan 40 mg to be the most consistently cost-effective choices.¹⁵

In practice, in a generic marketplace, the actual out-of-pocket cost for either drug often depends more on your insurance formulary or pharmacy pricing than on any intrinsic cost difference between the molecules. It is worth checking which one your plan covers at a lower tier before settling on a preference.

Formulations and Practical Convenience

Rizatriptan has one practical advantage that matters during a migraine: it comes in an orally disintegrating wafer (sometimes called an MLT or melt tablet) that dissolves on the tongue without water. When you are nauseous or away from a water source, that formulation is genuinely helpful. The preference trial that compared rizatriptan wafers with eletriptan tablets found both drugs equally tolerable, but the option of a wafer is something eletriptan simply does not offer.¹⁶ Eletriptan is only available as a conventional tablet.

That said, the orally disintegrating form does not actually get absorbed faster through the mouth lining; it still has to reach the stomach and intestine like any other oral medication. The convenience is real, the speed advantage is mostly a myth. Both drugs reach peak blood levels in roughly one to two hours after swallowing, though individual absorption can vary depending on how much gastric slowing your migraine is causing.

Who Should Choose Which

Given the evidence, here are the scenarios where one drug tends to be the better fit:

Frequent recurrence: If your migraines tend to come back within 24 hours of initial relief, eletriptan’s stronger sustained-response data makes it the logical first pick.
Taking a CYP3A4 inhibitor: If you are on ketoconazole, certain HIV medications, or clarithromycin, avoid eletriptan. Rizatriptan is safer here.
Taking an MAO inhibitor: Rizatriptan is contraindicated. Eletriptan is the better option.
Taking propranolol: Rizatriptan can still be used but at a reduced 5 mg dose. Eletriptan avoids this complication entirely.
Nausea at onset: If vomiting or severe nausea hits early in your attacks, rizatriptan’s dissolving wafer provides a more practical delivery method.
Need for a higher dose option: Eletriptan can be prescribed at 80 mg when 40 mg is not enough. Rizatriptan’s ceiling is 10 mg per dose.

For people who do not fall into any of these categories, the choice is genuinely close, and many headache specialists will start with whichever one is cheaper on your formulary or easier to get. If it works, there is little reason to switch. If it does not, the other is worth trying before giving up on the triptan class altogether.

How Triptans Fit Alongside Newer Migraine Drugs

The migraine treatment landscape has expanded considerably in recent years with the arrival of gepants (such as ubrogepant and rimegepant) and ditans (lasmiditan). These newer classes work through entirely different mechanisms and do not carry the cardiovascular cautions that come with all triptans. For people who cannot use triptans at all, whether due to heart disease, uncontrolled hypertension, or a history of stroke, gepants and ditans have filled a real gap.

But for those who can safely take triptans, eletriptan and rizatriptan remain among the most effective acute treatments available. The newer drugs generally show lower two-hour response rates in head-to-head-adjacent comparisons, and they cost substantially more, especially in countries where generic triptans are available for a few dollars per dose. Gepants do have a unique advantage in being usable as both acute and preventive therapy, something no triptan can claim. Ditans carry notable drowsiness and driving restrictions that can limit their practical appeal. The realistic picture is not that newer drugs have replaced triptans but that they have expanded the toolkit for people whom triptans failed or who cannot take them safely.